ViiV Healthcare receives approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment Read more
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease Read more
Servier Announces FDA Approval of TIBSOVO (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS) Read more
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer Read more
Bristol Myers Squibb Announces FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis Read more
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets Read more
Astraveus awarded €10.4 million grant by the French government as part of France 2030 investment plan Read more
Clinical Trial Application (IND) for BioRay Pharmaceutical’s BR105 Injection Receives U.S. FDA Approval Read more